top of page

ArcanaBio's Rapid Saliva-Based COVID-19 Test Achieves 94.3% Sensitivity in Comparative Trial

ArcanaBio, today announced exceptional results from a clinical trial for the companys new rapid saliva-based COVID-19 test. Achieving a sensitivity rate of 94.3% against the Cobas 8800, a state of the art qPCR robot run by the Virology lab of the National University Hospital of Iceland. The test also reported 90% of all positive results in less than 20 minutes, with the overall test time being around 50 minutes.

The clinical trial, which was conducted with the approval of the Bioethics Committee of Iceland, with a special permission granted from Persónuvernd, the Icelandic Data Protection Authority, that included over 175 participants ranging from infants, teenager to adults.

The success of ArcanaBio's saliva test could revolutionise COVID-19 testing protocols by offering a non-invasive, user-friendly, and efficient alternative to current testing methods. This could prove particularly beneficial for testing in sensitive populations such as infants and children.

ArcanaBio's milestone achievement contributes significantly to global efforts against the COVID-19 pandemic. The company looks forward to the further implementation and wider availability of the test in the near future. More details will be released soon.


Commenting has been turned off.
bottom of page